One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!

Anthony Hughes Biography and Net Worth

CAO of Amyris

Presently, Anthony Hughes holds the position of Chief Accounting Officer at Amyris, Inc.

In his past career Mr. Hughes held the position of Chief Accounting Officer of ServiceSource International, Inc., Senior Director-Accounting Policy, Reporting & Tax at Blackhawk Network Holdings, Inc., Controller at LECG Corp. and Chief Accounting Officer of CRC Health Corp.

Anthony Hughes received a graduate degree and an undergraduate degree from the University of North Texas.

What is Anthony Hughes' net worth?: The estimated net worth of Anthony Hughes is at least $0.00 as of June 2nd, 2022. Mr. Hughes owns 106,612 shares of Amyris stock worth more than $0 as of April 25th. This net worth evaluation does not reflect any other investments that Mr. Hughes may own. Learn More about Anthony Hughes' net worth.
How do I contact Anthony Hughes?: The corporate mailing address for Mr. Hughes and other Amyris executives is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. Amyris can also be reached via phone at (510) 450-0761 and via email at [email protected]. Learn More on Anthony Hughes' contact information.
Has Anthony Hughes been buying or selling shares of Amyris?: Anthony Hughes has not been actively trading shares of Amyris within the last three months. Most recently, Anthony Hughes sold 6,305 shares of the business's stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $2.34, for a transaction totalling $14,753.70. Following the completion of the sale, the chief accounting officer now directly owns 106,612 shares of the company's stock, valued at $249,472.08. Learn More on Anthony Hughes' trading history.
Who are Amyris' active insiders?: Amyris' insider roster includes Eduardo Alvarez (COO), Anthony Hughes (CAO), Nicole Kelsey (Insider), Hermanus Kieftenbeld (CFO), Frank Kung (Director), James McCann (Director), and John Melo (CEO). Learn More on Amyris' active insiders.
Are insiders buying or selling shares of Amyris?: During the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 20,999 shares worth more than $19,949.05. The most recent insider tranaction occured on June, 2nd when CFO Hermanus Kieftenbeld sold 20,999 shares worth more than $19,949.05. Insiders at Amyris own 36.3% of the company. Learn More about insider trades at Amyris.
Information on this page was last updated on 6/2/2023.

Anthony Hughes Insider Trading History at Amyris

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/2/2022	Sell	6,305	$2.34	$14,753.70	106,612
9/2/2021	Sell	1,162	$14.86	$17,267.32	82,917

Anthony Hughes Buying and Selling Activity at Amyris

Amyris Company Overview

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Today's Range

Now: N/A

50 Day Range

MA: $0.54

$0.05

$1.17

2 Week Range

Now: N/A

Volume

46,746,000 shs

Average Volume

12,593,118 shs

Market Capitalization

$18.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

The World's First "$20 Trillion Drug?"

From Behind the Markets | Ad

Get the name of the stock here >>>